The Role of NSAIDs in Breast Cancer Prevention and Relapse: Current Evidence and Future Perspectives | Zendy

Demetrios Moris | Zendy; Michalis Kontos | Zendy; Eleftherios Spartalis | Zendy; Ian S. Fentiman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Role of NSAIDs in Breast Cancer Prevention and Relapse: Current Evidence and Future Perspectives

Author(s) -

Demetrios Moris,

Michalis Kontos,

Eleftherios Spartalis,

Ian S. Fentiman

Publication year - 2016

Publication title -

breast care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.767

H-Index - 30

eISSN - 1661-3805

pISSN - 1661-3791

DOI - 10.1159/000452315

Subject(s) - medicine , aspirin , breast cancer , cyclooxygenase , cancer , inflammation , oncology , cancer prevention , bioinformatics , pharmacology , enzyme , biochemistry , chemistry , biology

Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) have received considerable interest as potential chemopreventive agents. The aim of this review is to summarize the accumulated knowledge on the effect of NSAIDs on breast cancer incidence and natural history, and the underlying pathophysiology. NSAIDs mainly block inflammation by inhibiting cyclooxygenase enzymes, leading to lower prostaglandin synthesis. The latter has been reported to affect breast cancer risk through hormonal and inflammation-related pathways. Intensity, dose, frequency, duration, and timing of administration may also be significant. There is currently enough evidence to support a role of NSAIDs in breast cancer prevention and relapse, which deserves further large-scale experimental and clinical investigation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research